Prolonged Overall Survival After Pulmonary Metastasectomy in Patients With Breast Cancer

Meimarakis, G.; Rüttinger, Dominik; Stemmler, Joachim; Crispin, Alexander; Weidenhagen, R.; Angele, Martin K.; Fertmann, Jan; Hatz, Rudolf; Winter, Hauke

doi:10.1016/j.athoracsur.2012.11.043

Cited by 61 publications

(48 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the study by Friedel et al the subgroup of patients with repeat metastasectomy achieved a 40 % five-year survival rate which was better than that of the study collective overall (35 %) [2]. Following repeated metastasectomy median post-metastasectomy survival was approximately 47 months in the study by Meimarakis et al [11]. The favourable long-term survival following repeat metastasectomy may seem surprising since an aggressive primary tumour/high tumour cell load can be assumed.…”

Section: Survival After Metastasis Surgerymentioning

confidence: 51%

“…Pulmonary metastasectomy resulted in a median post-metastasectomy survival of 32 to 96.6 months (▶ Table 2) [2][3][4][5][8][9][10][11]. Five-year survival rates were between 30.8 and 54.4 %, while 10-year survival rates were between 18 and 51 % [2][3][4][5][6][7][8][9][10].…”

Section: Survival After Metastasis Surgerymentioning

confidence: 99%

“…Ten of the reviewed studies were case series, together reporting on over 971 patients with treated breast carcinoma and pulmonary metastasectomy [2][3][4][5][6][7][8][9][10][11]. Operations were performed between 1960 and 2007.…”

Section: Methodsmentioning

confidence: 99%

“…The literature search performed on 15 February 2017 had 2426 hits in MEDLINE and found one review article in the Cochrane library. After step-wise appraisal 11 studies where identified each with at least 20 patients having had lung metastasectomy following primary tumour treatment with curative intent [2][3][4][5][6][7][8][9][10][11][12].…”

Section: Methodsmentioning

confidence: 99%

“…Median follow-up for the case series was between 20.6 and 102 months [4,[7][8][9][10][11]. Pulmonary metastasectomy resulted in a median post-metastasectomy survival of 32 to 96.6 months (▶ Table 2) [2][3][4][5][8][9][10][11].…”

Section: Survival After Metastasis Surgerymentioning

confidence: 99%

See 4 more Smart Citations

Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma

Macherey

Mallmann

Malter

et al. 2017

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

ABSTR AC TBreast carcinoma with pulmonary metastasis can be treated locally or systemically. Following primary tumour resection patients with isolated, completely resectable pulmonary nodules and definite functional operability can be offered lung metastasis resection. Following metastasectomy a median survival of 32 to 96.6 months can be achieved with corresponding five-year survival rates between 30.8 and 54.4 %. The procedure is associated with a mortality rate of 0 to 3 %. The most important independent prognostic factor for longterm survival is complete resection of all lung lesions. The configuration and pattern of metastasis as well as disease-free interval, hormone and HER2/neu receptor status also appear to influence prognosis, but are of lesser importance. Intrapulmonary recurrence of metastases may, after careful selection on a case-by-case basis, also be treated operatively. In some cases this is associated with a favourable long-term prognosis. Pulmonary metastasectomy should be the treatment of choice for selected patients with metastatic breast carcinoma. ZUSAMMENFASSUNG

show abstract

Section: Survival After Metastasis Surgerymentioning

confidence: 51%

Section: Survival After Metastasis Surgerymentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Survival After Metastasis Surgerymentioning

confidence: 99%

See 3 more Smart Citations

Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma

Macherey

Mallmann

Malter

et al. 2017

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

show abstract

Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011

et al. 2016

View full text Add to dashboard Cite

IMPORTANCE Management of the primary tumor site in patients with metastatic breast cancer remains controversial. OBJECTIVE To evaluate the patterns of receipt of initial breast surgery for female patients with stage IV breast cancer in the United States, with particular attention to women who survived at least 10 years. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) program. Female patients diagnosed as having stage IV breast cancer between 1988 and 2011 and who did not receive radiation therapy as part of the first course of treatment were included (N = 21 372). Kaplan-Meier estimates of median survival and descriptive statistics were used to compare patient and tumor characteristics by receipt of breast surgery at diagnosis. A Royston-Parmar survival model and logistic regression analysis assessed demographic and clinical factors associated with survival and prolonged survival (of at least 10 years). MAIN OUTCOMES AND MEASURES Differences in survival, particularly survival of at least 10 years, by receipt of initial surgery to the primary tumor. RESULTS Among the 21 372 patients, the median survival increased from 20 months (1988–1991) to 26 months (2007–2011). During this time, the rate of surgery declined (odds ratio [OR], 0.16; 95% CI, 0.12–0.21). Even so, receipt of surgery was associated with improved survival in multivariate analysis, which controlled for patient and clinical characteristics, along with time period (hazard ratio, 0.60; 95% CI, 0.57–0.63). For women diagnosed as having cancer before 2002 (n = 7504), survival of at least 10 years was seen in 9.6%(n = 353) and 2.9% (n = 107) of those who did and did not receive surgery, respectively (OR, 3.61; 95% CI, 2.89–4.50). In multivariate analysis, survival of at least 10 years was associated with receipt of surgery (odds ratio, 2.80; 95% CI, 2.08–3.77), hormone receptor–positive disease (OR, 1.76; 95% CI, 1.25–2.48), older age (OR, 0.41; 95% CI, 0.32–0.54), larger tumor size (OR, 0.37; 95% CI, 0.27–0.51), marital status of being separated at the time of diagnosis (OR, 0.67; 95% CI, 0.51–0.88), and more recent year of diagnosis (OR, 1.43; 95% CI, 1.02–1.99). CONCLUSIONS AND RELEVANCE Survival in stage IV breast cancer has improved and is increasingly of prolonged duration, particularly for some women undergoing initial breast surgery. As systemic therapy advances provide better control of distant disease in stage IV breast cancer, and as women present with lower distant disease burdens, these findings on initial surgery to the primary tumor may be of importance.

show abstract

Oligometastatic breast cancer: Are we there yet?

AlSendi

O’Reilly

Zeidan

et al. 2021

Intl Journal of Cancer

View full text Add to dashboard Cite

Patients with metastatic breast cancer are usually considered incurable. Recent advances have resulted in significant improvements in survival for patients with metastatic breast cancer. Due to the lack of randomised trials and heterogeneous disease biology, treatment decisions for patients with oligometastatic breast cancer vary widely. Some patients are treated similar to those with widespread disease while others are treated more aggressively. We conducted a review of the evidence for treatment options in oligometastatic breast cancer and consulted ClinicalTrials.gov to explore currently accruing or studies in development aimed at investigating oligometastatic disease in breast cancer. Surgery to the primary tumour in patients with metastatic breast cancer has failed to show any advantage over systemic therapy. However, there may be a benefit in women with controlled systemic disease who are hormone receptor positive with bone‐predominant metastasis. Stereotactic radiotherapy has gained increased interest in this setting due to its excellent efficacy and lower rates of associated toxicity. A significant challenge remains in identifying the patient population who would benefit from such an approach, and to do so, we need to understand the distinct biology of oligometastatic breast cancer. Unique miRNA expression and low levels of tumour infiltrating lymphocytes in the immune micro‐environment have been described in tumour tissues in patients with oligometastatic breast cancer. There is ongoing research aimed to better characterise these tumours, thus, allowing the selection of patients who would truly benefit from multi‐modality treatment in an attempt for long‐term survival and cure.

show abstract

Prolonged Overall Survival After Pulmonary Metastasectomy in Patients With Breast Cancer

Cited by 61 publications

References 37 publications

Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma

Lung Metastasectomy for Pulmonary Metastatic Breast Carcinoma

Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011

Oligometastatic breast cancer: Are we there yet?

Contact Info

Product

Resources

About